{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:26:56Z","timestamp":1760149616766,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background: FV Leiden is an autosomal dominant disease, representing one of the most prevalent genetic causes for hereditary thrombophilia manifested by venous thromboembolism. Methods: We report a case of a 30-year-old patient who was admitted for enrollment in phase II cardiac rehabilitation. The cardiovascular disease onset was five years ago when the patient was diagnosed with superficial vein thrombosis, for which anticoagulant treatment was recommended. However, he discontinued the prescribed treatment independently, which resulted in the development of deep vein thrombosis. A screening for risk factors associated with venous thromboembolism was conducted, leading to the identification of a heterozygous mutation of factor V Leiden. Later, the patient was hospitalized for acute coronary syndrome necessitating stent implantation. Following this procedure, the patient started a cardiac rehabilitation program, where the patient received multidisciplinary counseling. Conclusions: At the end of the cardiac rehab, significant improvements were observed in clinical and hemodynamic parameters. Consequently, the patient was advised to continue rehabilitation treatment in the outpatient setting. Also, for patients with suboptimal maintenance of the therapeutic range of INR, the use of apixaban might be considered. Furthermore, the utilization of a reduced dosage of apixaban has demonstrated its effectiveness in preventing further venous thromboembolism.<\/jats:p>","DOI":"10.3390\/reports6030039","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T09:10:56Z","timestamp":1692695456000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges of a Patient with Thromboembolism"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-9581","authenticated-orcid":false,"given":"Andra","family":"Oancea","sequence":"first","affiliation":[{"name":"Department of Medical Specialties I, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-9696","authenticated-orcid":false,"given":"Alexandra","family":"Ma\u0219taleru","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina Mihaela","family":"Abdulan","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8544-9904","authenticated-orcid":false,"given":"Alexandru Dan","family":"Costache","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4053-4130","authenticated-orcid":false,"given":"M\u0103d\u0103lina Ioana","family":"Zota","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Negru","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4140-0492","authenticated-orcid":false,"given":"\u0218tefana","family":"Mois\u0103","sequence":"additional","affiliation":[{"name":"Department of Mother and Child, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Mihaela","family":"Trandafir","sequence":"additional","affiliation":[{"name":"Department of Mother and Child, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Magdalena","family":"Leon","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-0039-1687906","article-title":"A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency","volume":"45","author":"Tabibian","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Badescu, M.C., Butnariu, L.I., Costache, A.D., Gheorghe, L., Seritean Isac, P.N., Chetran, A., Leanc\u0103, S.A., Afr\u0103s\u00e2nie, I., Duca, \u0218.-T., and Gorduza, E.V. (2023). Acute Myocardial Infarction in Patients with Hereditary Thrombophilia\u2014A Focus on Factor V Leiden and Prothrombin G20210A. Life, 13.","DOI":"10.3390\/life13061371"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1161\/01.CIR.0000068167.08920.F1","article-title":"Cardiology patient page. Factor V Leiden","volume":"107","author":"Ornstein","year":"2003","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10654-013-9825-8","article-title":"Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: A meta-analysis involving over 11,000 cases and 21,000 controls","volume":"28","author":"Simone","year":"2013","journal-title":"Eur. J. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2012-02-407551","article-title":"Broadening the factor V Leiden paradox: Pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum","volume":"120","author":"Flinterman","year":"2012","journal-title":"Blood"},{"key":"ref_6","first-page":"104569","article-title":"Homozygous factor V leiden mutation: Rare etiology of pulmonary embolism","volume":"82","author":"Bouzhir","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.thromres.2008.01.013","article-title":"Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins","volume":"123","author":"Milio","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1034\/j.1600-0404.2000.102001031.x","article-title":"Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis","volume":"102","author":"Stolz","year":"2000","journal-title":"Acta Neurol. Scand."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00277-004-0921-4","article-title":"Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: Results of a single-center case-control study","volume":"83","author":"Mostafa","year":"2004","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/j.1538-7836.2010.03982.x","article-title":"The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease","volume":"8","author":"Mannucci","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/01.STR.0000170635.45745.b8","article-title":"Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke\/transient ischemic attack up to the age of 60 years","volume":"36","author":"Lalouschek","year":"2005","journal-title":"Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/2047487320913379","article-title":"Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology","volume":"28","author":"Ambrosetti","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/eurheartj\/ehad225","article-title":"Global perspectives on heart disease rehabilitation and secondary prevention: A scientific statement from the Association of Cardiovascular Nursing and Allied Professions, European Association of Preventive Cardiology, and International Council of Cardiovascular Prevention and Rehabilitation","volume":"44","author":"Taylor","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_14","unstructured":"Authors\/Task Force Members, ESC Committee for Practice Guidelines (CPG), and ESC National Cardiac Societies (2019). 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 290, 140\u2013205."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/archinte.164.15.1675","article-title":"Hyperthyroidism and risk of atrial fibrillation or flutter: A population-based study","volume":"164","author":"Frost","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/europace\/eun289","article-title":"Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter","volume":"11","author":"Mont","year":"2009","journal-title":"Europace"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.hrthm.2011.03.038","article-title":"Smoking and incidence of atrial fibrillation: Results from the Atherosclerosis Risk in Communities (ARIC) study","volume":"8","author":"Chamberlain","year":"2011","journal-title":"Heart Rhythm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/jce.14526","article-title":"The arrhythmogenic right ventricular cardiomyopathy in comparison to the athletic heart","volume":"31","author":"Mascia","year":"2020","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/jce.13410","article-title":"The long-QT syndrome and exercise practice: The never-ending debate","volume":"29","author":"Mascia","year":"2018","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.amjmed.2016.11.016","article-title":"Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation","volume":"130","author":"Tzoran","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e021115","DOI":"10.1161\/JAHA.120.021115","article-title":"Factor V Leiden and the Risk of Bleeding in Patients with Acute Coronary Syndromes Treated with Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials","volume":"10","author":"Mahmoodi","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor\u2019s Choice\u2014European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.14398","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: A systematic review and meta-analysis","volume":"17","author":"Elsebaie","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"ref_26","first-page":"486","article-title":"Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: Findings from START2 register study","volume":"18","author":"Margaglione","year":"2020","journal-title":"Blood Transfus."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12185-020-03012-7","article-title":"Direct oral anticoagulants in patients with severe inherited thrombophilia: A single-center cohort study","volume":"113","author":"Zuk","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.thromres.2020.10.020","article-title":"Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia","volume":"196","author":"Serrao","year":"2020","journal-title":"Thromb. Res."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/6\/3\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:39:05Z","timestamp":1760128745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/6\/3\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["reports6030039"],"URL":"https:\/\/doi.org\/10.3390\/reports6030039","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}